World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
60
Citations
15986
World Ranking
11795
National Ranking
907

Overview

Anna Schuh is affiliated with the University of Oxford in the United Kingdom and has contributed extensively to research in the fields of medicine and biochemistry, genetics, and molecular biology. Their work spans various subfields including genetics, pathology and forensic medicine, cancer research, oncology, and molecular biology.

The scientist's research primarily focuses on topics related to chronic lymphocytic leukemia, lymphoma diagnosis and treatment, cancer genomics and diagnostics, viral-associated cancers and disorders, acute lymphoblastic leukemia, genetic factors in colorectal cancer, and acute myeloid leukemia.

Notable recent publications by Anna Schuh include:

  • The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms, 2022, Leukemia
  • The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms, 2022, Leukemia
  • Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease, 2023, New England Journal of Medicine
  • SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications, 2020, Leukemia
  • Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial, 2023, The Lancet Oncology

Frequent co-authors in Schuh's research include:

  • Toby A. Eyre
  • Piers Patten
  • Peter Hillmen
  • Christopher P. Fox
  • Andrew R. Pettitt

The scientist's work has been published in several prominent venues, reflecting a consistent focus on hematology and oncology research. Common publication venues include:

  • Blood
  • British Journal of Haematology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Leukemia
  • HemaSphere

The scope of Anna Schuh's research encompasses multiple aspects of cancer biology and hematologic diseases, contributing to the understanding and treatment strategies in these areas.

Best Publications

  • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

    J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos

  • Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

    Jan A. Burger;Alessandra Tedeschi;Paul M. Barr;Tadeusz Robak

  • Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Bonnie Harrington;Susan O'Brien;Jeffrey A. Jones

  • Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia

    Nicolas Goardon;Emanuele Marchi;Ann Atzberger;Lynn Quek

  • Factors influencing success of clinical genome sequencing across a broad spectrum of disorders

    Jenny C. Taylor;Jenny C. Taylor;Hilary C. Martin;Stefano Lise;John Broxholme

  • Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns

    Anna Schuh;Jennifer Becq;Sean Humphray;Adrian Alexa

  • Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

    Stephan Stilgenbauer;Barbara Eichhorst;Johannes Schetelig;Peter Hillmen

  • SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage

    Ruth Clifford;Tania Louis;Pauline Robbe;Sam Ackroyd

  • Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.

    Peter Hillmen;Andy C. Rawstron;Kristian Brock;Samuel Muñoz-Vicente

  • Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy

    Chulin Sha;Sharon Barrans;Francesco Cucco;Michael A. Bentley

  • Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations

    Andrea Pellagatti;Richard N. Armstrong;Violetta Steeples;Eshita Sharma

  • Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial

    Andrew R. Pettitt;Richard Jackson;Stacey Carruthers;James Dodd

  • Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia

    David Oscier;Claire Dearden;Efrem Eren;Christopher Fegan

  • The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom.

    Katharina Schwarze;James Buchanan;James Buchanan;Jilles M Fermont;Helene Dreau

  • ETO-2 associates with SCL in erythroid cells and megakaryocytes and provides repressor functions in erythropoiesis

    Anna H. Schuh;Alex J. Tipping;Allison J. Clark;Isla Hamlett

  • Genetic variation at MECOM , TERT , JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms

    William Tapper;Amy V. Jones;Robert Kralovics;Ashot S. Harutyunyan

  • Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.

    Viktor Ljungström;Diego Cortese;Emma Young;Tatjana Pandzic

  • Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.

    C. Craddock;C. Craddock;L. Quek;N. Goardon;S. Freeman;S. Freeman

  • Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project

    Pauline Robbe;Niko Popitsch;Samantha J L Knight;Pavlos Antoniou

  • Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.

    Romain Guièze;Pauline Robbe;Ruth Clifford;Sophie de Guibert

Frequent Co-Authors

Peter Hillmen
Peter Hillmen St James's University Hospital
Jenny C. Taylor
Jenny C. Taylor University of Oxford
Samantha J.L. Knight
Samantha J.L. Knight University of Oxford
Paolo Ghia
Paolo Ghia Vita-Salute San Raffaele University
Jennifer R. Brown
Jennifer R. Brown Harvard University
Paresh Vyas
Paresh Vyas University of Oxford
David Oscier
David Oscier Royal Bournemouth Hospital
John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Tadeusz Robak
Tadeusz Robak Medical University of Lodz
Andy C. Rawstron
Andy C. Rawstron Leeds Teaching Hospitals NHS Trust

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Biology and Biochemistry opens doors to diverse career paths, many of which now offer flexible, online degree options. If you're interested in healthcare data and administration, consider pursuing an online health information management degree. This pathway prepares you to manage patient records and work with medical systems, offering both job stability and opportunities for advancement.

Another in-demand option is medical coding. The medical coding salary is competitive, and the field requires strong biological and medical knowledge. If you want to know whether this is the right field for you, check out the medical coding job outlook for insights into job prospects, work environments, and growth potential.

For those passionate about health at the molecular level, a nutrition masters online can expand your expertise. This degree can lead to positions in clinical practice, research, or public health initiatives, all of which benefit from a background in biology or biochemistry.

Best Scientists Citing Anna Schuh

Trending Scientists

Recently Published Articles